Nrx pharmaceuticals reports second quarter 2023 financial results and provides business update

Two near-term data catalysts expected in 2023 entered active collaboration with alvogen pharmaceuticals and lotus pharmaceuticals for global development and commercialization of nrx-101 in suicidal bipolar depression; potential for up to $330 million in milestones and double-digit royalties publication of stabil-b trial in the international journal of bipolar disorders: first oral antidepressant to demonstrate reduction in suicidality with significant improvement in depression scores compared to standard of care medication ongoing phase 2b/3 trial of nrx-101 in suicidal bipolar depression is within 20 patients of data readout. data expected in q4 2023 newly released data demonstrate high levels of compliance and inter-rater reliability licensed us patent for use of d-cycloserine (dcs) to treat chronic pain announced plan to develop nrx-101™   for chronic pain indications, awaiting results of 200 person dod-funded trial in treatment of chronic pain with dcs in coming months filing investigational new drug application with fda to treat chronic pain with nrx-101 management to host a conference call today at 4:30 pm et radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking